The Relative Strength (RS) Rating for UroGen Pharma entered a higher percentile Monday, as it got a lift from 67 to 77.
Can You Really Time The Stock Market?
This unique rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
History shows that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating as they launch their largest climbs. See if UroGen Pharma can continue to rebound and hit that benchmark.
UroGen Pharma is not currently offering a proper buying opportunity. See if the stock goes on to build a promising consolidation that could kick off a new climb.
UroGen Pharma showed 0% EPS growth last quarter, while sales growth came in at 8%.
The company holds the No. 194 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Anbio Biotechnology and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
